Bernhard H.
- Country
- Germany
- Department
- Klinik für Hämatologie und Onkologie
Research Overview
- Randomized Phase II Study of Teclistamab + Daratumumab‑Lenalidomide‑Dexamethasone (Tec‑DRd) vs Daratumumab‑Lenalidomide‑Dexamethasone (DVRd) in Transplant‑Eligible NDMM
- Efficacy and Safety Comparison of Obinutuzumab-Venetoclax vs. Obinutuzumab-Chlorambucil in Untreated CLL with Comorbidities
- Venetoclax in combination with the BTK inhibitor Ibrutinib and Rituximab or conventional chemotherapy (Bendamustine) and Ibrutinib and Rituximab in patients with treatment naive Mantle Cell Lymphoma not eligible for high dose therapy
Data & Insights
Has run more than one trial at 121 of 295 partner sites.
Specializations
Multiple Myeloma Research
Specialized in investigating novel therapeutic approaches for newly diagnosed multiple myeloma, with particular focus on combination therapies and maintenance strategies.
- Isatuximab-based combination therapies
- Post-transplant maintenance protocols
- Minimal residual disease assessment
Expertise in evaluating both intravenous and subcutaneous administration routes for targeted therapies.
Leukemia Treatment
Focuses on innovative treatments for acute lymphoblastic leukemia and chronic lymphocytic leukemia, particularly in previously untreated patients.
- Philadelphia-chromosome positive ALL therapy
- Targeted molecular treatments
- Combined immunotherapy approaches
Specializes in developing treatment strategies for patients with coexisting medical conditions.
Lymphoma Studies
Expert in treating various lymphoma types, including follicular lymphoma and mantle cell lymphoma, with focus on early-stage and advanced disease management.
- Novel combination therapies
- Radiotherapy optimization
- Targeted antibody treatments
Investigates innovative approaches combining chemotherapy with targeted biological agents.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.